1-3 of 3
Vassiliki Poulaki, MD, PhD
Close
Sort by
Journal Articles

The mTOR Inhibitor RAD001 (everolimus) Is Active Against Multiple Myeloma Cells In Vitro and in Vivo.

Nicholas Mitsiades, MD, PhD, Ciaran McMullan, MSc, Vassiliki Poulaki, MD, PhD, Joseph Negri, Noopur Raje, MD, Shaji Kumar, MD, Despoina Sikoutri, Teru Hideshima, MD, PhD, Dharminder Chauhan, PhD, Paul G. Richardson, MD, Robert L. Schlossman, MD, Andrew L. Kung, MD, PhD, Heidi Lane, PhD, Nikhil C. Munshi, MD, PhD, Kenneth C. Anderson, MD, Constantine S. Mitsiades, MD, PhD
Journal: Blood
Blood (2004) 104 (11): 1496.
https://doi.org/10.1182/blood.V104.11.1496.1496
Published: 2004
Journal Articles

NVP-AEW541: A Selective Small Molecule IGF-1R Tyrosine Kinase Inhibitor Is Active Against Multiple Myeloma and Other Hematologic Neoplasias and Solid Tumors.

Nicholas Mitsiades, MD, PhD, Ciaran J. McMullan, Vassiliki Poulaki, MD, PhD, Reshma Shringarpure, PhD, Towia A. Libermann, PhD, Teru Hideshima, MD, PhD, Dharminder Chauhan, PhD, Robert L. Schlossman, MD, Paul G. Richardson, MD, Nikhil C. Munshi, MD, PhD, Carlos Garcia-Echeverria, PhD, Francesco Hoffmann, PhD, Kenneth C. Anderson, MD, Constantine S. Mitsiades, MD, PhD
Journal: Blood
Blood (2004) 104 (11): 766.
https://doi.org/10.1182/blood.V104.11.766.766
Published: 2004
Journal Articles

Avicins: A Novel Class of Anti-Myeloma Agents.

Nicholas Mitsiades, MD, PhD, Ciaran J. McMullan, MSc, Vassiliki Poulaki, MD, PhD, Joseph Negri, David C. Geer, MSc, Valsala Haridas, PhD, Nikhil C. Munshi, MD, PhD, Jordan Gutterman, MD, Kenneth C. Anderson, MD, Constantine S. Mitsiades, MD, PhD
Journal: Blood
Blood (2004) 104 (11): 3405.
https://doi.org/10.1182/blood.V104.11.3405.3405
Published: 2004